SCHEMBL10748552

SCHEMBL10748552

COc1c(O)ccc(CO)c1CO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.39
CA4 P22748 1/20 0.39
MAPT P10636 1/20 0.38
KLF10 Q13118 1/20 0.36
CA1 P00915 2/20 0.36
CA12 O43570 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
PDE4A P27815 4/20 0.36
PDE4B Q07343 4/20 0.36
PDE4C Q08493 4/20 0.36
PDE4D Q08499 4/20 0.36
PDE5A O76074 3/20 0.36
PDE1A P54750 3/20 0.36
PDE1B Q01064 3/20 0.36
PDE3B Q13370 3/20 0.36
PDE1C Q14123 3/20 0.36
PDE3A Q14432 3/20 0.36
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11231888 0.89 TRPV1 (0.37) CA2CA4MAPTKLF10CA1
SCHEMBL4486140 0.88 MAPT (0.40) CA2MAPTKLF10CA1CA12
SCHEMBL26046493 0.85 HMGCR (0.43) CA2CA4TRPV1POLB
SCHEMBL22545546 0.83 ALOX5 (0.44) MAPTCYP3A4KDM4EALDH1A1GAA
SCHEMBL17008599 0.82 KDM4E (0.39) CA2MAPTKLF10CA1CA12
SCHEMBL7948321 0.81 BCL2 (0.41) CYP3A4SMN1; SMN2POLB
SCHEMBL26046416 0.81 IAPP (0.45) MAPTTRPV1PKMCYP3A4KDM4E
SCHEMBL26046355 0.81 POLB (0.55) MAPTTDP1TRPV1KDM4EALDH1A1
SCHEMBL11238058 0.81 KLF10 (0.38) MAPTKLF10PKMKDM4EALDH1A1
SCHEMBL14539258 0.80 PDCD1 (0.39) CA2MAPTKLF10CA1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760773-B2 Small molecule drug conjugates of gemcitabine monophosphate MAVERIX ONCOLOGY, INC. (US) 2023-09-19 US disclosed
CN-101678333-B Process for preparing a hydroxyaromatic aldehyde RHODIA OPERATIONS 2014-01-01 CN disclosed
US-4683087-A 2,2-ETHYLENE BIS(6-BROMOMETHYL-P-BENZOQUINONE THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1987-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760773-B2 Small molecule drug conjugates of gemcitabine monophosphate ZYX, SLC7A5, GMPS CA2 3394/4885CA4 1387/4885MAPT 4486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.